Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E, Freedman MS, Stuart W, Cunha L, Jacobs L, Oger J, Arnold D, Murray TJ, DiBiase M, Jethwa V, Goelz S. Phillips JT, et al. Among authors: jacobs l. Clin Ther. 2004 Apr;26(4):511-21. doi: 10.1016/s0149-2918(04)90053-7. Clin Ther. 2004. PMID: 15189748 Clinical Trial.
A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis.
Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, Mocci S. Goodkin DE, et al. Among authors: jacobs l. Neurology. 2000 Apr 11;54(7):1414-20. doi: 10.1212/wnl.54.7.1414. Neurology. 2000. PMID: 10751249 Clinical Trial.
What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B, Jacobs LD. Weinstock-Guttman B, et al. Among authors: jacobs ld. Drugs. 2000 Mar;59(3):401-10. doi: 10.2165/00003495-200059030-00002. Drugs. 2000. PMID: 10776827 Review.
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH, et al. Rudick RA, et al. Among authors: jacobs ld. J Neuroimmunol. 1999 Jan 1;93(1-2):8-14. doi: 10.1016/s0165-5728(98)00174-x. J Neuroimmunol. 1999. PMID: 10378864 Clinical Trial.
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.
Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, Granger CV, Simon JH, Grafman JH, Lezak MD, O'Reilly Hovey KM, Perkins KK, Barilla-Clark D, Schacter M, Shucard DW, Davidson AL, Wende KE, Bourdette DN, Kooijmans-Coutinho MF. Fischer JS, et al. Among authors: jacobs ld. Ann Neurol. 2000 Dec;48(6):885-92. Ann Neurol. 2000. PMID: 11117545
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE 3rd, Cookfair DL, Simon JH, Jacobs LD. Rudick RA, et al. Among authors: jacobs ld. Neurology. 1998 May;50(5):1266-72. doi: 10.1212/wnl.50.5.1266. Neurology. 1998. PMID: 9595973 Clinical Trial.
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Whitham RH, et al. Rudick RA, et al. Among authors: jacobs ld. Neurology. 1997 Aug;49(2):358-63. doi: 10.1212/wnl.49.2.358. Neurology. 1997. PMID: 9270562 Clinical Trial.
Advances in specific therapy for multiple sclerosis.
Jacobs L, Goodkin DE, Rudick RA, Herndon R. Jacobs L, et al. Curr Opin Neurol. 1994 Jun;7(3):250-4. doi: 10.1097/00019052-199406000-00012. Curr Opin Neurol. 1994. PMID: 8081519 Review.
1,751 results